Novartis has agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Under the terms of the agreement, Novartis will make an upfront payment of $925 million upon closing of the transaction, subject to certain customary adjustments, and potential additional payments of up to $2.15 billion upo...